LINKER-MM1 Study in RRMM | Naresh Bumma, MD | ASH 2022

Individualized Approach to Treating AML Patients | Pamela Becker, MD, PhD | ASH 2022

New Therapies in AML - Menin Inhibitor Revumenib (SNDX-5613) | Eytan M. Stein, MD | ASH 2022

Venetoclax and Azacitidine in Newly Diagnosed AML Patients | Dan Pollyea, MD, MS | ASH 2022

Nutrivention Trials | Urvi Shah, MD | ASH 2022

Building a Dietary Evidence Symposium | Urvi Shah, MD | ASH 2022

T Cell Redirection Therapy | Tarek Mouhieddine, MD | ASH 2022

Bispecifics | Urvi Shah, MD | ASH 2022

CAR-T Therapy | Santiago Thibaud, MD | ASH 2022

CAR-T BMS-986354 | Luciano Costa, MD, PhD | ASH 2022

Maintenance Cessation in MRD Negative Patients | Neha Korde, MD | ASH 2022

Maintenance Cessation in MRD Negative Patients | Neha Korde, MD | ASH 2022

Effect of a Covid Infection in Patients Prior to Transplant | Meera Mohan, MD, MS, FACP | ASH 2022

New Developments at ASH | Rafat Abonour, MD | ASH 2022

Quad Therapies and Side Effects | Nathan Sweeney, PhD | ASH 2022

Patient Top Concerns At and Since Diagnosis | Nathan Sweeney, PhD | ASH 2022

Bispecific T Cell Engagers | Noopur Raje, MD | ASH 2022

Revlimid Refractory Patients in Daratumumab Clinical Trials | Binod Dhakal, MD | ASH 2022

MRD Detection in Blood | Bruno Paiva, PhD | ASH 2022

iStopMM Trial - Covid Vaccine and Impact on Myeloma | Malin Hultcrantz, MD, PhD | ASH 2022

Post BCMA Therapy | Gurbakhash Kaur, MD | ASH 2022

Updates on Teclistamab, Talquetamab, and CARVYKTI | Mark Wildgust, PhD | ASH 2022

Treatment vs Quality of Life in Older Patients | Sara Tinsley Vance, PhD, APRN | ASH 2022